Replies to post #102190 on Biotech Values

[oc631]

No—the ITMN-191 study you must be thinking of is the phase-2b in genotype-2/3 patients that has been “delayed” by Roche until 2011 (#msg-53150504).

Actually what I was referring to was the whole program.